Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.
Shannon N. Westin, MD, MPH, FACOG
Advertisement
Shannon Westin, MD, MPH, FACOG, the director of Early Drug Development and the Phase I Trials Department, and a professor in the Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, at The University of Texas MD Anderson Cancer Center.
Articles by Shannon N. Westin, MD, MPH, FACOG
Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.
Experts in gynecologic oncology discuss novel combination strategies for the treatment of advanced endometrial cancer.
Shannon N. Westin, MD, MPH, FACOG, and Vicky Makker, MD, comment on data from ongoing clinical trials presented at the Society of Gynecologic Oncology 2021 Virtual Annual Meeting on Women’s Cancer for the management of advanced endometrial cancer.
Experts in gynecologic oncology share insights on patient selection for lenvatinib-pembrolizumab in advanced endometrial cancer and discuss therapeutic sequencing through multiple lines of therapy.
Vicky Makker, MD, and Shannon N. Westin, MD, MPH, FACOG, discuss their experiences using lenvatinib-pembrolizumab therapy for advanced endometrial cancer.
Vicky Makker, MD, reviews the safety profile of lenvatinib-pembrolizumab in advanced endometrial cancer from the phase 3 KEYNOTE-775/Study 309 trial and the management of common adverse events.
Vicky Makker, MD, reviews the trial design and efficacy data for the open-label, randomized phase 3 KEYNOTE-775/Study 309 in patients with advanced endometrial cancer.
Upcoming Clinical Trials for Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Emerging Therapies in Recurrent Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Antibody Drug Conjugates for Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Neoadjuvant Therapy Versus Surgery for Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
New Data for Secondary Surgery in Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
PARP Inhibitors in Recurrent Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Expert Approaches for Treating Recurrent Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Emerging Combinations in the Frontline Setting of Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Patient Preference for Treatment in Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
PAOLA-1 Study Surgical Subset for Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
NCCN Guidelines and FDA Approvals for Treating Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Personalized Dosing of Niraparib in Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Treating Homologous Recombination Proficient Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Treating BRCA+ Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Need for Frontline Comparison Trials in Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Impact of HRD Status on Frontline Treatment of Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
The Impact of PAOLA-1 on Frontline Treatment of Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Biomarker-Driven Frontline Ovarian Cancer Treatment
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
An Introduction to the Discussion of Ovarian Cancer
ByBradley J. Monk, MD, FACOG, FACS, Creighton University School of Medicine at St. Joseph's Hospital and Arizona Oncology,Michael J. Birrer, MD, PhD, University of Arkansas Medical Center,Matthew Powell, MD, Washington University School of Medicine,Leslie Randall, MD, FACOG, VCU Health,Shannon N. Westin, MD, MPH, FACOG
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5